Kye Pharmaceuticals Inc. ("Kye"), a Canadian specialty pharmaceutical company, announced its partnership with Hyloris Pharmaceuticals SA ("Hyloris"), a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine. Through this partnership, Kye becomes the exclusive Canadian rights holder for the Atomoxetine Oral Solution developed by Hyloris. Under the terms of the agreement, Kye is responsible for the registration and commercialization of
Understanding ADHD, its causes, and symptoms is crucial for providing support for children with this neurodevelopmental condition. Strategies like managing distractions, planning, positive reinforcement, empathetic parenting, and promoting a healthy lifestyle can help.
The COVID-19 pandemic may have played a considerable role in the uptick of adults being treated for ADHD. But more data is needed to determine whether the trends will continue.